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transcriptional characterization of a
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Cancer of unknown primary (CUP) defines
a heterogeneous group of metastatic
tumors that lack an identifiable primary
tumor, despite a standardized diagnostic
work-up (Fizazi et al, 2015). CUPs are
characterized by an aggressive clinical
course, unusual metastatic pattern, and
poor prognosis. Research in this field has
been encouraged to unravel the complex-
ity of this enigmatic entity and improve
clinical management and survival of CUP
patients. In this issue of EMBO Molecular
Medicine, Benvenuti et al (2020) describe
the molecular characterization of multiple
synchronous and spatially distinct metas-
tases from a CUP patient, shedding light
on the evolutionary dynamic and distinc-
tive features of CUP.
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D espite the advances in medical imag-ing and molecular approaches, theprimary site cannot be identified at
the time of diagnosis in 1–2% of cancers
(Rassy & Pavlidis, 2020). The existence of
CUP as a real entity is further supported by
cases where the primary tumor cannot be
identified even after extensive diagnostic
work-up or exhaustive research of post-
mortem autopsy.
Clinical management of CUP patients is a
challenge in the oncology field. Efforts to
expand the therapeutic alternatives beyond
empirical chemotherapy to improve survival
have been centered on two different strate-
gies: traditional tissue-gnostic or tissue-
agnostic approaches. For the first, tumor-
type classification is the key to treatment
allocation. Tissue specificity of gene expres-
sion and epigenetic profiles (Moran et al,
2016) has guided the development of tumor-
type classifiers for CUPs (Moran et al,
2017). Case reports, case series, and non-
randomized prospective studies of CUPs
have indicated that tumor-type specific ther-
apies lead to improved outcomes; however,
randomized controlled trials have not clearly
demonstrated their superiority in compar-
ison with empirical chemotherapy (Fizazi
et al, 2019; Hayashi et al, 2019).
Considering that the tissue could no
longer be the focus in CUPs, tissue-agnostic
approaches have also gained force in the last
years. Molecularly driven therapies have
already transformed the treatment landscape
of several tumors harboring actionable
mutations, independently of the tissue of
origin. Along these lines, the ongoing phase
II, randomized clinical trial CUPISCO
(NCT03498521) will compare the efficacy
of molecularly guided therapy versus
standard platinum-based chemotherapy in
CUP cases.
Although the lack of a primary tumor in
CUPs could be explained by limited sensitiv-
ity of imaging technologies for detecting
very small tumors, or the possibility that the
primary tumor regresses or remains
dormant, the existence of metastases that
develop following a distinctive biological
pathway different to the canonical meta-
static cascade remains to be explored
(Fig 1).
In an effort to improve our knowledge on
this enigmatic entity, Benvenuti et al (2020)
describe in this issue of EMBO Molecular
Medicine the molecular characterization of
multiple synchronous and spatially distinct
metastases from a CUP patient. A total of 15
metastases were retrieved at warm autopsy
from nine different tissues of a 49-year-old
male patient. Whole-exome sequencing
(WES) and RNA sequencing (RNAseq) were
performed on 15 and 6 metastases, respec-
tively. The comprehensive genomic and
transcriptomic data generated in this report
offer a unique opportunity to study the
mechanistic origin and evolution of CUPs.
WES analysis identified a total of 748
nonsynonymous mutations in the 15 metas-
tases, 276 of them were fully shared. Inter-
estingly, the genetic similarity among all
metastases pairs ranged from 58 to 82%,
revealing a low degree of inter-metastases
heterogeneity. A similar scenario has
recently been described in treatment-naive
metastases from patients with tumors of
known primary, where 66% of the muta-
tions per patient were clonal (homogeneous)
among metastases (Reiter et al, 2019).
Genetic homogeneity seems to be the rule
rather than the exception in both scenarios,
leaving room for the identification of poten-
tially druggable targets to simultaneously
eradicate multiple lesions. Moreover,
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considering the aggressive nature and rapid
clinical course of CUPs, the presence of
strong clonal oncogenic driver mutations
could also explain the lack of heterogeneity
in the CUP metastases.
Genomic data of several metastases from
the same CUP patient are also an optimal
setting to infer tumor evolutionary dynam-
ics. Since the complexity of cancer arises
from evolutionary processes of mutations,
genetic drift, and selection, use of genomic
sequencing is an invaluable tool to under-
stand temporal and spatial patterns of
somatic evolution (Turajlic et al, 2019).
Although in Benvenuti et al (2020)
methodological limitations related to sample
type (bulk sequencing) and depth of cover-
age (< 50× in about 60% of targeted base
pairs) could diminish the accuracy of their
inferences, the authors suggest that the
phylogenetic tree reconstruction of CUP
metastases is consistent with the presence of
a common cell of origin with stem-like
features that disseminate its progeny, an
attractive hypothesis to explain CUP origin
that merits further investigation.
The existence of cancer stem cells, first
described in hematopoietic tumors and later
in several solid tumors, has also been
proposed as a driver of metastasis. In the
case of CUPs, stem cell attributes such as
migratory ability, plasticity, and high
renewal capacity could explain metastatic
dissemination without the requirement of
establishing a primary tumor. CUP metas-
tases might originate from stem cells or non-
stem cells that have acquired these biologi-
cal properties due to DNA alterations, and
are able to settle and colonize different
organs. The phenotypic plasticity and undif-
ferentiated state of these cells could also be
behind the unpredictable metastatic patterns
observed in CUPs, in contrast to the metasta-





























Figure 1. Hypothesized origins of CUP.
(A) Small primary tumors undetectable with available imaging technologies; (B) primary tumors that regress or remain dormant; (C) metastases that develop following a
distinctive biological pathway, different to the canonical metastatic cascade of dissemination from a primary tumor, perhaps from cells with stem cell attributes.
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An additional layer of information, the
transcriptomes of six CUP metastases, has
also been analyzed by Benvenuti et al
(2020). To our knowledge, this is the most
comprehensive series of metastases from a
case of CUP reported in the literature and is
per se a valuable contribution to scientific
knowledge.
Transcriptomic analysis of the CUP
metastases revealed a lack of correlation
with The Cancer Genome Atlas (TCGA)
datasets of 33 different tumor types, a
finding certainly unexpected. Although the
unique features of CUPs could arise from a
distinctive transcriptome, this conclusion
contrasts with the achievement of CUP clas-
sifiers based on tissue-specific expression
profiles (Moran et al, 2017). Further studies
to support this finding are encouraged, as
well as inclusion of series of stem cells/
stem-like cells in the correlation analysis.
Besides, additional caution should be taken
considering that CUP samples analyzed in
this study derived from warm autopsy.
Research autopsy approach holds a
tremendous potential to contribute to under-
stand physiological and pathological condi-
tions. However, even over relatively short
timeframes, death introduces a bias in cellu-
lar transcriptomes. Using mRNA sequencing
data from multiple tissues of post-mortem
donors obtained from the Genotype Tissue
Expression (GTEx) database, a recent
systematic study found that the post-mortem
interval (PMI) impacts RNA stability in a
very tissue-dependent manner (Ferreira
et al, 2018). The comparison of transcrip-
tomes of TCGA normal tissue counterparts
with normal tissues obtained at warm
autopsy of the same CUP patient could
further support the unique transcriptomic
profile of the CUP metastases reported by
the authors.
Multicentric, multidisciplinary, and
multiomics studies are needed to decipher
the biological and clinical complexity of
CUPs. With this aim, the TCGA program, the
major effort to catalog the molecular alter-
ations in cancer, has launched a multiomic
project under our coordination to character-
ize CUPs encompassing genomic, transcrip-
tomic, and epigenomic data. This project
aims at expanding our knowledge on the
molecular mechanisms governing CUP
carcinogenesis and will also be key to assess
the existence of different CUP entities, and
to identify potential therapeutic targets that
can be translated to clinical practice. Finally,
increasing examples of successful use of
immunotherapies in several tumor types
encourages the scientific community to
explore this approach to improve the dismal
outcome of CUP patients.
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